Your browser doesn't support javascript.
loading
An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment.
Sharifi, Majid; Cho, William C; Ansariesfahani, Asal; Tarharoudi, Rahil; Malekisarvar, Hedyeh; Sari, Soyar; Bloukh, Samir Haj; Edis, Zehra; Amin, Mohamadreza; Gleghorn, Jason P; Hagen, Timo L M Ten; Falahati, Mojtaba.
  • Sharifi M; Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud 3614773947, Iran.
  • Cho WC; Department of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud 3614773947, Iran.
  • Ansariesfahani A; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
  • Tarharoudi R; Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran 1916893813, Iran.
  • Malekisarvar H; Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran 1916893813, Iran.
  • Sari S; Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran 1916893813, Iran.
  • Bloukh SH; Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran 1916893813, Iran.
  • Edis Z; Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman P.O. Box 346, United Arab Emirates.
  • Amin M; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman P.O. Box 346, United Arab Emirates.
  • Gleghorn JP; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman P.O. Box 346, United Arab Emirates.
  • Hagen TLMT; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman P.O. Box 346, United Arab Emirates.
  • Falahati M; Laboratory Experimental Oncology and Nanomedicine Innovation Center Erasmus, Department of Pathology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
Cancers (Basel) ; 14(12)2022 Jun 10.
Article en En | MEDLINE | ID: mdl-35740534
ABSTRACT
The enhanced permeability and retention (EPR) effect in cancer treatment is one of the key mechanisms that enables drug accumulation at the tumor site. However, despite a plethora of virus/inorganic/organic-based nanocarriers designed to rely on the EPR effect to effectively target tumors, most have failed in the clinic. It seems that the non-compliance of research activities with clinical trials, goals unrelated to the EPR effect, and lack of awareness of the impact of solid tumor structure and interactions on the performance of drug nanocarriers have intensified this dissatisfaction. As such, the asymmetric growth and structural complexity of solid tumors, physicochemical properties of drug nanocarriers, EPR analytical combination tools, and EPR description goals should be considered to improve EPR-based cancer therapeutics. This review provides valuable insights into the limitations of the EPR effect in therapeutic efficacy and reports crucial perspectives on how the EPR effect can be modulated to improve the therapeutic effects of nanomedicine.
Palabras clave